Infermedica, the Poland-founded well being tech startup that provides an AI-driven platform for preliminary analysis and triage, has raised simply over $10 million in Series A funding.
The spherical is led by the European Bank for Reconstruction and Development (EBRD) and digital well being fund Heal Capital. Existing buyers Karma Ventures, Inovo Venture Partners, and Dreamit Ventures additionally participated.
Infermedica says the funding might be used for platform R&D to additional improve its affected person triage and symptom checking options and medical determination help evaluation. The firm can also be planning to broaden operations in Germany and the U.S. The new capital means the startup has raised $15 million in complete so far.
Founded in 2012 in Wrocław by CEO Piotr Orzechowski, Infermedica describes itself an “AI-driven, customisable, multi-language” platform that aids affected person care and healthcare service supply. Like a plethora of rivals, similar to Ada Health, Babylon and Your.MD, it combines the experience of medical doctors with its personal algorithms to supply symptom triage and recommendation to sufferers.
Notably, the corporate operates a B2B mannequin, working with insurance coverage corporations, telemedicine corporations, and well being methods that wish to supply digitally delivered symptom-checks. It positions itself as “API-first,” in addition to whitelabeling its platform on behalf of consumers.
“We’re targeted on enhancing the best way sufferers make selections about their signs,” explains Orzechowski. “According to research, the vast majority of web customers search on-line once they’re feeling unwell, but it surely’s onerous to search out correct and personalised solutions about our personal well being. To assist everybody consider their signs in a fast and dependable means, we’ve developed a rigorously curated AI platform that asks diagnostic questions and computes likelihoods of major care circumstances. With practically 40,000 hours of doctor work and 6,000,000 accomplished consumer checkups, we’re among the many most trusted distributors of symptom checking expertise”.
To that finish, present Infermedica shoppers embody medical health insurance corporations, similar to Allianz, Global Excel, and Medis,, the place digital triage claims to assist optimise the price of offering care. The startup additionally sells into hospital methods, together with Sana Kliniken, and is used to establish the urgency of a affected person’s case and to gather data previous to a hospital go to. It additionally provides its API to expertise corporations, similar to Microsoft, who combine the platform into its well being bot.
On competitors, Orzechowski says that there are a number of “nice corporations” within the house, however argues that every of them does one thing completely different when it comes to their product or advertising and marketing focus. “What makes Infermedica distinctive is that we’re API-first,” he says. “We’re solely targeted on offering essentially the most highly effective AI triage and pre-diagnosis part, and we combine simply with all different platforms similar to chatbots, affected person portals, and EHRs. We wish to turn out to be like Stripe, however for medical analysis”.
Meanwhile, Infermedica makes cash by licensing its expertise to its B2B shoppers. The startup’s SaaS mannequin sees it cost primarily based on the variety of carried out API calls or accomplished affected person checkups.